Biocon Biologics' Bengaluru Unit Classified as Voluntary Action Indicated by US FDA
Overview
Biocon Biologics said its drug substance facility in Bengaluru has been classified as voluntary action indicated by the US Food and Drug Administration.
Drug Facility Location & Statemenet
The company’s drug substance facility is located at Biocon Campus, (Site 1) in Bengaluru, the company said in a statement.
"This relates to the cGMP inspection conducted by the agency between February 20-28, 2024 and pertains to the supply of rh-Insulin (rhI) drug substance to the United States," it added.
Regarding Regulatory Actions
Under voluntary action indicated (VAI), while objectionable conditions were found and documented during an inspection, the agency is not prepared to take or recommend regulatory action, as per the US FDA.
Biocon Biologics remains committed to global standards of quality and compliance, the company said.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!